BR112016026369A2 - combinações de formoterol e budesonida para tratamento de copd. - Google Patents

combinações de formoterol e budesonida para tratamento de copd.

Info

Publication number
BR112016026369A2
BR112016026369A2 BR112016026369-3A BR112016026369A BR112016026369A2 BR 112016026369 A2 BR112016026369 A2 BR 112016026369A2 BR 112016026369 A BR112016026369 A BR 112016026369A BR 112016026369 A2 BR112016026369 A2 BR 112016026369A2
Authority
BR
Brazil
Prior art keywords
formoterol
budesonide
combinations
copd treatment
copd
Prior art date
Application number
BR112016026369-3A
Other languages
English (en)
Inventor
Ullmann
Michiel
Original Assignee
Teva Pharmaceuticals Europe B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51032625&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016026369(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceuticals Europe B.V. filed Critical Teva Pharmaceuticals Europe B.V.
Publication of BR112016026369A2 publication Critical patent/BR112016026369A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112016026369-3A 2014-05-12 2015-05-08 combinações de formoterol e budesonida para tratamento de copd. BR112016026369A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1408387.7 2014-05-12
GBGB1408387.7A GB201408387D0 (en) 2014-05-12 2014-05-12 Treatment of respiratory disorders
PCT/EP2015/060257 WO2015173154A1 (en) 2014-05-12 2015-05-08 Combinations of fomoterol and budesunide for the treatment of copd

Publications (1)

Publication Number Publication Date
BR112016026369A2 true BR112016026369A2 (pt) 2018-05-15

Family

ID=51032625

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112016026369-3A BR112016026369A2 (pt) 2014-05-12 2015-05-08 combinações de formoterol e budesonida para tratamento de copd.
BR112016026371-5A BR112016026371A2 (pt) 2014-05-12 2015-05-08 combinações de tiotropio bromida, formoterol e budesonida para tratamento de copd

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112016026371-5A BR112016026371A2 (pt) 2014-05-12 2015-05-08 combinações de tiotropio bromida, formoterol e budesonida para tratamento de copd

Country Status (17)

Country Link
US (2) US20170202858A1 (pt)
EP (2) EP3142654A1 (pt)
JP (4) JP2017515835A (pt)
KR (2) KR20170003601A (pt)
CN (2) CN106488770A (pt)
AR (2) AR100369A1 (pt)
AU (2) AU2015261104A1 (pt)
BR (2) BR112016026369A2 (pt)
CA (2) CA2948553A1 (pt)
CL (1) CL2016002848A1 (pt)
EA (2) EA201692278A1 (pt)
GB (1) GB201408387D0 (pt)
IL (2) IL248874A0 (pt)
MX (2) MX2016014695A (pt)
PE (1) PE20170073A1 (pt)
UA (2) UA119773C2 (pt)
WO (2) WO2015173154A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104758294A (zh) * 2014-12-17 2015-07-08 广州呼吸疾病研究所 用于copd、哮喘治疗的吸入药物组合物及其制备方法
TW201735914A (zh) * 2015-12-22 2017-10-16 阿斯特捷利康公司 用於治療慢性阻塞性肺疾病之醫藥組成物
CN106466322A (zh) * 2016-08-25 2017-03-01 杭州百诚医药科技股份有限公司 一种以布***和噻托溴铵为活性成分的复方制剂
WO2018071425A1 (en) 2016-10-11 2018-04-19 Microdose Therapeutx, Inc. Inhaler and methods of use thereof
WO2019142214A1 (en) 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
US20200398004A1 (en) * 2018-02-23 2020-12-24 Microdose Therapeutx, Inc. Inhaler and Methods of Use Thereof
CN116077471A (zh) * 2021-11-08 2023-05-09 上海臣邦医药科技股份有限公司 一种供吸入用的粉雾剂组合物及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0613371B1 (en) * 1991-12-18 2002-03-06 AstraZeneca AB New combination of formoterol and budesonide
CA2356145A1 (en) * 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
UA80123C2 (en) * 2002-04-09 2007-08-27 Boehringer Ingelheim Pharma Inhalation kit comprising inhalable powder of tiotropium
SE526509C2 (sv) * 2003-06-19 2005-09-27 Microdrug Ag Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd
US20070293460A1 (en) * 2005-10-31 2007-12-20 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
EP2049086A2 (en) * 2006-08-09 2009-04-22 Glaxo Group Limited Process for manufacturing lactose
KR20090121338A (ko) * 2007-02-19 2009-11-25 씨아이피엘에이 엘티디. 두 개 이상의 기관지확장제 또는 기관지확장제와 코르티코스테로이드의 약제학적 조합
US20100329996A1 (en) * 2007-09-12 2010-12-30 Glaxo Group Limited Novel Combination of Therapeutic Agents
TR201000680A2 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler
MX2012012045A (es) * 2010-04-21 2012-12-17 Chiesi Farma Spa Proceso para proporcionar particulas con cargas electrostaticas reducidas.
NZ605920A (en) * 2010-07-16 2015-01-30 Cipla Ltd Pharmaceutical compositions comprising r (+) budesonide and one or more bronchodilators
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
RU2460547C1 (ru) * 2011-04-08 2012-09-10 Валерий Феофанович Ушаков Способ пролонгированной профилактики холодового бронхоспазма у больных с "микст-патологией"
US20150165037A1 (en) * 2012-07-05 2015-06-18 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising corticosteroid and sorbitol
ITMI20130571A1 (it) * 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo

Also Published As

Publication number Publication date
EP3142653A1 (en) 2017-03-22
MX2016014695A (es) 2017-05-04
JP2020023537A (ja) 2020-02-13
IL248874A0 (en) 2017-01-31
WO2015173154A9 (en) 2016-03-03
UA119773C2 (uk) 2019-08-12
AU2015261103A1 (en) 2016-11-17
US20170202858A1 (en) 2017-07-20
UA119774C2 (uk) 2019-08-12
WO2015173153A1 (en) 2015-11-19
CA2948574A1 (en) 2015-11-19
BR112016026371A2 (pt) 2018-06-19
EA201692278A1 (ru) 2017-02-28
CN106488770A (zh) 2017-03-08
PE20170073A1 (es) 2017-03-24
AR100368A1 (es) 2016-09-28
JP2020023536A (ja) 2020-02-13
GB201408387D0 (en) 2014-06-25
EA201692276A1 (ru) 2017-03-31
CN106470700A (zh) 2017-03-01
AU2015261104A1 (en) 2016-11-17
EP3142654A1 (en) 2017-03-22
KR20170003601A (ko) 2017-01-09
JP2017515835A (ja) 2017-06-15
US20170209464A1 (en) 2017-07-27
MX2016014696A (es) 2017-05-04
KR20170003600A (ko) 2017-01-09
JP2017515833A (ja) 2017-06-15
CL2016002848A1 (es) 2017-07-07
AR100369A1 (es) 2016-09-28
IL248875A0 (en) 2017-01-31
WO2015173154A1 (en) 2015-11-19
CA2948553A1 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
FIC20230014I1 (fi) Foslevodopa ja foskarbidopa
BR112015002968A2 (pt) dispositivo para vestir e método para fabricar o mesmo
BR112017011771A2 (pt) métodos e composições para o tratamento de câncer
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
BR112016021682A2 (pt) cenicriviroc para o tratamento da fibrose
BR112016027041A2 (pt) Combinações farmacêuticas para tratamento do câncer
DK3231444T3 (da) Ny behandling
DK3192518T3 (da) Anti-inflammatorisk middel
DOS2016000088S (es) Recipientes para dispositivos medicos
DK3103715T3 (da) Styreindretning og styringsfremgangsmåde dertil
DK3206740T3 (da) Forstøvere
BR112016022976A2 (pt) Métodos para o tratamento de hcv
BR112016026369A2 (pt) combinações de formoterol e budesonida para tratamento de copd.
FR3018779B1 (fr) Conditionnement
DK3138583T3 (da) Dekontamineringssystem
DK3364753T4 (da) Blandevogn
DK3166473T3 (da) Oftalmoskoper
KR20180084835A (ko) 2성분 필라멘트
BR112016024667A2 (pt) composições de revestimento melhorado e processos para fabricação das mesmas
BR112017005376A2 (pt) inibidores de mao-b e reabilitação.
ES1123030Y (es) Dispositivo para aplicacion de crioterapia
ES1149360Y (es) Dispositivo para braquiterapia
ES1136381Y (es) Apósito para laparoscopia
DK3183264T3 (da) Pegyleringsfremgangsmåde
BR112016023407A2 (pt) programação semi-persistente para eimta em lte

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements